NCT06530030Terminated
Goal Attainment and Physical Activity in People With Hemophilia A
Prospective, Observational Study of the Impact of Efanesoctocog Alfa (ALTUVIIIO®) on Goal Attainment and Physical Activity in People With Moderate or Severe Hemophilia A
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan. This study aims to enroll 35 patients.
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 3 (actual)
- First submitted
- 17 Jul 2024
- Start date
- 26 Nov 2024
- Primary completion date
- 18 Sept 2025
- Lead sponsor
- Sanofi
- Diseases
- Haemophilia
- NCT number
- NCT06530030
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current diagnosis of a FVIII inhibitor, defined as inhibitor titer ≥ 0.60 BU/mL
- Use of efanesoctocog alfa for prophylaxis in the 6 months prior to enrollment
- NOTE: Other Inclusion/Exclusion criteria may apply. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Who the study is looking for
- At enrollment, newly starting prophylaxis therapy with efanesoctocog alfa according to usual clinical practice, with efanesoctocog alfa initiated within 6 months after the enrollment visit
- Diagnosis of moderate (endogenous FVIII activity between 1% to 5% of normal) or severe (endogenous FVIII activity <1% of normal) hemophilia A
- Aged 12 to 50 years at time of enrollment, inclusive
- Access to a smartphone device (Android version 12.0 or higher; or iOS 13 or higher) with Bluetooth 4.0 (minimum) or 5.0 (recommended) capabilities for compatibility with physical activity tracker
- Availability of home-based access to internet for electronic patient-reported outcome (ePRO)/diary assessments
- Willingness to utilize the activity tracking device
Age in the registry: 12 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bleeding and Clotting Disorders Institute Coordinator of this site? Confirm its status | Peoria | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.